CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
March 12 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, announced today that CEO
Steven Engle will participate in a fireside chat with Research
Analyst Jason McCarthy at the Inaugural Emerging Growth Conference
presented by M Vest LLC and Maxim Group LLC. Mr. Engle will also
present a company overview, which will be available on demand. The
conference will be held virtually March 17 – 19, 2021.
Maxim Emerging Growth
Conference |
|
Friday, March
19, 2021 at 2:30 PM ET |
|
Webcast: The presentation may be accessed via
webcast following the presentation, using the following link:
https://www.m-vest.com/events/2021-emerging-growth-virtual-conference.
Registration is required. |
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring peptide sequences within the mitochondrial
genome, some of which have been shown to have the
potential to regulate key processes
in multiple systems and organs in the body. To date,
the company has discovered more than 100 mitochondrial derived
peptides and generated over 1,000 analogs. CohBar’s efforts focus
on the development of these peptides into therapeutics that offer
the potential to address a broad range of diseases associated
with the underlying impact of mitochondrial dysfunction. The
company’s lead compound, CB4211, is in the Phase 1b stage of a
Phase 1a/1b clinical trial for NASH and obesity. In addition,
CohBar has four preclinical programs: CB5138 Analogs for
fibrotic diseases, CB5064 Analogs for COVID-19 associated
ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases,
and MBT3 Analogs for cancer immunotherapy.
For additional company information, please visit
www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking statements which are
not historical facts within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based
only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies,
projections, anticipated events and other future conditions. In
some cases you can identify these statements by forward-looking
words such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “should,” “would,” “project,”
“plan,” “expect,” “goal,” “seek,” “future,” “likely” or the
negative or plural of these words or similar expressions. Examples
of such forward-looking statements include but are not limited to
statements regarding timing and anticipated outcomes of research
and clinical trials for our mitochondria based therapeutic (MBT)
candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ
materially from those set forth in these forward-looking
statements. Factors that could cause actual results to differ
materially from these forward-looking statements include: our
ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials; our possible inability to mitigate the prevalence and/or
persistence of the injection site reactions, receipt of unfavorable
feedback from regulators regarding the safety or tolerability of
CB4211 or the possibility of other developments affecting the
viability of CB4211 as a clinical candidate or its commercial
potential; results that are different from earlier data results
including less favorable than and that may not support further
clinical development; our ability to raise additional capital when
necessary to continue our operations; our ability to recruit and
retain key management and scientific personnel; the risk that our
intellectual property may not be adequately protected; our ability
to establish and maintain partnerships with corporate and industry
partners; and risks related to the impact on our business of the
COVID-19 pandemic or similar public health crises. Additional
assumptions, risks and uncertainties are described in detail in our
registration statements, reports and other filings with the
Securities and Exchange Commission and applicable Canadian
securities regulators, which are available on our website, and at
www.sec.gov or www.sedar.com.
You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024